International Journal of Antimicrobial Agents
Volume 13, Issue 3 , Pages 183-187 , January 2000

Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection

  • A.P Menday

      Affiliations

    • Corresponding Author InformationTel.: +44-1844-347333; fax: +44-1844-346088

Received 19 July 1999 ,Accepted 30 July 1999.

References 

  1. Select Committee on Science and Technology. Sub-committee 1 (House of Lords), 7th report (session 1997–8): resistance to antibiotics and other antimicrobial agents, [HL]81-1. The Stationery Office, London, 1998.
  2. Standing Medical Advisory Committee (Department of Health). The path of least resistance, Main report. Department of Health, London, 1998.
  3. Rosdahl, V.T., Pedersen, K.B., editors. The Copenhagen Recommendations. Report from the Invitational EU Conference on the Microbial Threat, 9–10 September, Copenhagen, Denmark. Ministry of Health, Ministry of Food, Agriculture and Fisheries, Denmark, 1998.
  4. Wise R, Hart T, Cars O, et al.  Antimicrobial resistance is a major threat to public health. Br. Med. J. 1998;317:609–610
  5. Sutlieff PA. A comparison between a 3-day and a 5-day course of pivmecillinam as a treatment for acute lower urinary tract infection in general practice. Curr. Med. Res. Opin. 1982;7:563–568
  6. Richards HH. Comparative efficacy of 3-day and 7-day chemotherapy with twice-daily pivmecillinam in urinary tract infections seen in general practice. Curr. Med. Res. Opin. 1984;9:197–203
  7. Hansen PH, Kristensen KH, Lenler-Eriksen HA, et al.  Pivmecillinam (Selexid®) in the treatment of acute cystitis. Comparison of three and seven days’ treatment. Ugerskr. Laeg. 1981;143:670–673
  8. Hovelius B, Mardh PA, Nygaard-Pedersen L, Wathne B. Nalidixic acid and pivmecillinam for treatment of acute lower urinary tract infections. Scand. J. Primary Health Care. 1985;3(Suppl 4):227–232
  9. Pitkajarvi T, Pyykonen M-L, Kannisto K, Piippo T, Viita P. Pivmecillinam treatment in acute cystitis. Drug Res. 1990;40:1156–1158
  10. Performance standards for antimicrobic disc susceptibility tests. National Committee for Clinical Laboratory Standards, 1979.
  11. British Society for Antimicrobial Chemotherapy Working Party . The clinical evaluation of antibacterial drugs. J. Antimicrob. Chemother. 1989;23(suppl. B):1–42
  12. Donald JF, Rimmer DMD. An open evaluation of a 3-day course of pivmecillinam (ten 200 mg tablets) in women with uncomplicated ystitis. J. Int. Med. Res. 1980;8:112–117
  13. Bitsch M, Hvass Hansen P, Pagh J. Treatment of acute cystitis. A comparison of a three day course of pivmecillinam (Selexid®) and a six day course of sulphamethizide. J. Drug Ther. Res. 1984;9:26–28
  14. Ashby JP, Andrews JM, Wise R. Development of a standardised method of disc testing to determine the sensitivity of mecillinam to UTI pathogens using methodology based on the BSAC standardised method of disc testing. J. Antimicrob. Chemother. 1999;44(suppl. A):122
  15. Cars O (Ed.). Antimicrobial Susceptibility Testing in Sweden. Scand J Infect Dis 1997;105(suppl 3).
  16. BSAC Standardised disc sensitivity testing method. Newsletter of the British Society for Antimicrobial Chemotherapy (Bermingham). Summer 1998.
  17. Winstanley TG, Linb DI, Eggington R, Hancock F. A 10-year survey of the antimicrobial susceptibility of urinary tract isolates in the UK: the Microbe Base project. J. Antimicrob. Chemother. 1997;40:591–594
  18. Piddock LJV. Fluoroquinolone resistance. Br. Med. J. 1998;317:1029–1030

PII: S0924-8579(99)00118-1

International Journal of Antimicrobial Agents
Volume 13, Issue 3 , Pages 183-187 , January 2000

Article Tools